Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Recruiting · NCT05835466 · Registry updated 2026-05-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 2 | 2026-05-06 | NCT05835466 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dompé Farmaceutici S.p.A | 5 |
| Icahn School of Medicine at Mount Sinai | 256 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University | Atlanta | United States | 262 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| NewYork-Presbyterian/Weill Cornell Medical Center | New York | United States | 5 |
| Roswell Park Cancer Institute | Buffalo | United States | 382 |
| Ruttenberg Treatment Center | New York | United States | 3 |
| The Cleveland Clinic Foundation | Cleveland | United States | 55 |
| The Ohio State University | Columbus | United States | 191 |
| Wake Forest Baptist Health Comprehensive Cancer Center | Winston-Salem | United States | 3 |